Medtronic ACM Chief Medical Officer Dr. Sam Ajizian Departs Amid Strategic Business Restructuring

Sep 08, 2024 18:30 CST Updated 18:30

Medtronic

Chronic Disease Medical Device and Therapy Developer

China Medical Procurement Network

China Medical Device Procurement Public Service Platform

Source |SiYu MedTech

On August 29, Sam Ajizian, MD, Chief Medical Officer of Medtronic's Acute Care and Monitoring (ACM), announced on LinkedIn that he would be leaving the company.

Personal Resume

Samuel Ajizian, M.D., Chief Marketing Officer of Patient Monitoring, Vice President of Global Clinical Research and Medical Science, is also a board-certified pediatric critical care physician with over 20 years of clinical practice experience in the pediatric ICU.

He earned his medical degree at the University of Southern California, completed his pediatric residency and served as chief resident at Children's Hospital Los Angeles. He then joined the United States Air Force, serving as a pediatrician and flight surgeon in an F-16 squadron.

Joined Medtronic in 2015, initially serving as the Vice President of Medical Affairs for the Patient Monitoring and Recovery business unit.

In 2018, he led MITG's Medical Safety Office. Ajizian later became the interim head of MITG's Scientific Communications team, overseeing the creation of key compliance-related deliverables, including Clinical Evaluation Reports.

In 2020, Dr. Ajizian served as the Chief Medical Officer of Medtronic Patient Monitoring and the Vice President of Global Clinical Research and Medical Science.

Medtronic's ACM Business

As the epidemic situation stabilizes, the demand for ventilators in the market decreases, leading to a decline in the profitability of the ventilator business.

On February 20, 2024, Medtronic Global CEO Geoff Martha announced via teleconference: the closure of the ventilator business and the merger of its remaining patient monitoring and respiratory intervention businesses into the Acute Care & Monitoring (ACM) operating division, as part of Medtronic's Medical Surgical portfolio.

Medtronic Exits Ventilator Product Line, andMerge and reorganize the remaining Patient Monitoring and Respiratory Interventions (PMRI) business into the ACM department.

The company will reinvest the funds saved from exiting the ventilator business into the ACM division, with a particular focus on remote patient monitoring.

The ACM department will includePulse Oximeters, Remote Patient Monitoring, Airway Management and Respiratory Monitoring Products, to meet the needs of different patients.

Departing Executives

In the past few months, several executives have left Medtronic.

2In June 2024, Karen Parkhill of Medtronic, plc. plans to step down as Executive Vice President and Chief Financial Officer (CFO).`, accepting the position of Chief Financial Officer at global tech giant HP.`

June 2024,Medtronic Confirms Rob ten Hoedt, Executive Vice President and President of Global Regions, to RetireThis marks an important leadership change for the company.

Meanwhile, Endologix, as a company specializing in the medical device field,Hired two former leaders of Medtronic to join its top management team, serving as Chief Commercial Officer (CCO) and Chief Operating Officer (COO), respectively.

In May 2024, Bonnie Handke, a 25-year veteran of Medtronic, joined CVRx.She serves as the Vice President of Global Health Economics at Medtronic, overseeing policy and reimbursement for coronary and renal denervation, peripheral vascular health, structural heart disease, aortic, and cardiac surgery.

In March 2024, Gio Di Napoli, President of Medtronic's Gastrointestinal Business, and Ariel Mactavish, President of the Respiratory Interventions Division, announced their resignations.

Christopher Cleary, former Senior Vice President of Corporate Development at Medtronic, also left in March this year after serving for 10 years.

Medtronic Executive Vice President and President of the Medical Surgical Portfolio, Bob White, has also left.

Conclusion

Medtronic, as a global leading medical technology company, is undergoing a series of significant changes and strategic adjustments to adapt to the ever-changing market environment and the needs for future growth.

Along with the business adjustment, the companyFocus more on business areas with high growth potential and align with the company's strategic direction, and carry out organizational restructuring.，Including layoffs and early retirement plans to optimize operational efficiency.

At the same time, the company isImplement stricter cost management measures, to reduce costs and improve financial efficiency. AndIncrease Investment in Automation and Digital Technologies, in order to improve production efficiency, enhance product quality, and accelerate the pace of innovation.

These changes and initiatives demonstrate Medtronic's rapid response to the current market situation, as well as its proactive positioning for future development opportunities.

- END -